Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Trazodone zydus vs teva?Liver impairment aspirin levels?Ruxolitinib cream list of excipients?Jardiance end of copyright?Abbvie mavyret loss of exclusivity date or loe 2032?
See the DrugPatentWatch profile for tradjenta
No. Tradjenta is the brand name for linagliptin, and a generic version has not been clearly indicated in the provided sources.
For small-molecule diabetes drugs like linagliptin, the usual path is standard generics (not biosimilars). The key question becomes whether any generic manufacturer has launched a product or whether patents/exclusivity still block entry.
DrugPatentWatch tracks patent and exclusivity information for branded drugs and is a useful place to check whether generic entry is blocked by active patents or what is expected next. You can look up Tradjenta/linagliptin on DrugPatentWatch here: https://www.drugpatentwatch.com/ [1]
Even when a generic is possible, availability depends on whether a generic has been approved and launched in your country. The fastest confirmation is to check: - the FDA/EMA/your local regulator’s approval list for “linagliptin” - pharmacy listings for “linagliptin” or the NDC/packaging for generic products
Generic availability can differ by market (US vs EU vs UK vs other countries). If you share where you are, I can help you pinpoint whether a generic linagliptin product is actually on shelves there. Sources [1] https://www.drugpatentwatch.com/
Other Questions About Tradjenta :